The compound annual growth rate of total sales of animal vaccine industry in the past decade has reached about 7.6%. The market scale of pet vaccine in China is about 6.9 billion, and domestic pet vaccine has great development space.
national guidelines on compulsory immunization against animal diseases (2022-2025) issued
On January 7, the Ministry of agriculture and rural areas issued the national guidance on compulsory immunization against animal diseases (2022-2025), which proposed that the population immune density of compulsory immunization against animal diseases should be maintained at more than 90% all year round, the immune density of immunized livestock and poultry should reach 100%, and the qualified rate of immune antibodies against highly pathogenic avian influenza, foot-and-mouth disease and small ruminant disease should be maintained at more than 70% all year round.
Provinces can adopt various forms such as self immunization of farms (households), immunization of third-party service subjects and government purchase of services to comprehensively promote the work of “fight first and then supplement”, realize full coverage of large-scale farms (households) by the end of 2022, and gradually stop government bidding for compulsory immunization vaccine by the end of 2025.
The national agricultural and rural science and technology development plan for the 14th five year plan issued by the Ministry of agriculture and rural areas mentioned that by 2025, we will strive to break through a number of controlled “neck” technologies and short board technologies, greatly improve the original innovation ability in the agricultural field, steadily rank first in the world in the overall strength of agricultural science and technology, biological breeding, agricultural 5g application Animal vaccines and other fields are at the leading level in the world.
the concentration of animal vaccine industry accelerated
Historically, the animal protection industry has a high growth. according to the statistics of securities times · databao, the total output value of China’s veterinary medicine industry increased from 37 billion to 68.4 billion from 2011 to 2020, with an average annual compound growth rate of about 7.1%, of which the total sales of animal vaccine industry increased from 7.3 billion yuan to 14.2 billion yuan, with an average annual compound growth rate of about 7.6% . At the same time, the growth of head animal vaccine enterprises is significantly faster than that of the industry. The sales of the top ten enterprises increased from 3.3 billion yuan to 8.9 billion yuan, with an average annual compound growth rate of 10.2%. It can be seen that the concentration of animal vaccine industry is accelerating.
With the improvement of R & D and innovation ability of domestic animal vaccine enterprises, the domestic substitution process of pet vaccine market is expected to be further accelerated. The research report in August 2021 pointed out that according to the immunization process of pet dogs and cats, the market scale of China’s pet vaccine is about 6.9 billion, and the market share of foreign brands is more than 90%. Domestic pet vaccine has great development space.
transaction activity of animal vaccine concept stocks increased
Statistics show that as of January 7, there are 16 listed companies with animal vaccine business, with a total A-share market value of 178.4 billion yuan. Jinyu Bio-Technology Co.Ltd(600201) product categories cover more than 100 kinds of animal vaccines in four series: pigs, birds, ruminants and pets. It has the fixed-point production qualification of the Ministry of agriculture for three compulsory vaccines against foot-and-mouth disease, highly pathogenic avian influenza and brucellosis, of which the market share of foot-and-mouth disease vaccine ranks first in the industry.
Tecon Biology Co.Ltd(002100) is one of the eight designated manufacturers of foot-and-mouth disease vaccine in China. The company has the most complete variety of animal vaccines in China, including foot-and-mouth disease, avian influenza, small ruminant disease, brucellosis, classical swine fever, blue ear disease and other products.
The main products of Wuhan Keqian Biology Co.Ltd(688526) are non national compulsory immunization pig vaccines and poultry vaccines. It is one of the enterprises with the most abundant product types in China’s animal biological products industry. The company announced on January 4 that it plans to sign a joint development agreement with central China Agricultural University on avian influenza (H9 subtype), duck tambusu virus disease inactivated vaccine (hb19 strain + df2 strain), African classical swine fever virus ELISA antibody detection kit and African classical swine fever virus fluorescent microsphere anti physical examination test kit, Cooperative research and development of live vaccine of cat Sanlian (cat plague virus, cat calicivirus and cat herpesvirus).
From the performance of the secondary market, animal vaccine concept stocks have been rising since December 2021, with an average increase of 12.62%. Four stocks including Fujian Aonong Biological Technology Group Incorporation Limited(603363) , Pulike Biological Engineering Inc(603566) , Tecon Biology Co.Ltd(002100) , China Animal Husbandry Industry Co.Ltd(600195) increased by more than 20%. During this period, Beijing Dabeinong Technology Group Co.Ltd(002385) , Shanghai Hile Bio-Technology Co.Ltd(603718) , Wuhan Keqian Biology Co.Ltd(688526) , Fujian Aonong Biological Technology Group Incorporation Limited(603363) , Jinyu Bio-Technology Co.Ltd(600201) of which Beijing Dabeinong Technology Group Co.Ltd(002385) received more than 10 million yuan of additional positions from financing customers, with the amount of 700 million yuan ranking first.
Compared with last month, the transaction activity has increased significantly since new year’s day. Data treasure statistics show that more than half of the average daily turnover of concept stocks since January has doubled compared with the previous month. The daily average turnover of 7 shares, including Shanghai Hile Bio-Technology Co.Ltd(603718) , Fujian Aonong Biological Technology Group Incorporation Limited(603363) , Wuhan Keqian Biology Co.Ltd(688526) , Qingdao Vland Biotech Inc(603739) , Pulike Biological Engineering Inc(603566) , Tech-Bank Food Co.Ltd(002124) , Shanghai Shen Lian Biomedical Corporation(688098) , increased by more than 2 times month on month.
From the research report data of securities companies, we can see the overall performance of animal vaccine concept stocks. According to the statistics of databao, according to the unanimous prediction of more than five institutions, Jinyu Bio-Technology Co.Ltd(600201) , Wuhan Keqian Biology Co.Ltd(688526) , Pulike Biological Engineering Inc(603566) , China Animal Husbandry Industry Co.Ltd(600195) , Tianjin Ringpu Bio-Technology Co.Ltd(300119) and other net profits in 2021, 2022 and 2023 will be increased by more than 10% in advance.
(source: Data treasure)
